25063-69-8

Basic information

• Product Name: 5 - [[(6 - Methoxypyridin - 3 - yl)aMino]Methylidene] - 2,2 - diMethyl - 1,3 - dioxane - 4,6 - dione
• Synonyms: 5 - [[(6 - Methoxypyridin - 3 - yl)aMino]Methylidene] - 2,2 - diMethyl - 1,3 - dioxane - 4,6 - dione;5-((6-methoxypyridin-3-ylamino)methylene)-2,2-dimethyl-1,3-dioxane-4,6-dione
• CAS NO: 25063-69-8
• Molecular Formula: C₁₃H₁₄N₂O₅
• Molecular Weight: 278.26066
• EINECS: -0
• Mol File: 25063-69-8.mol

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 5 - [[(6 - Methoxypyridin - 3 - yl)aMino]Methylidene] - 2,2 - diMethyl - 1,3 - dioxane - 4,6 - dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5 - [[(6 - Methoxypyridin - 3 - yl)aMino]Methylidene] - 2,2 - diMethyl - 1,3 - dioxane - 4,6 - dione(25063-69-8)
• EPA Substance Registry System: 5 - [[(6 - Methoxypyridin - 3 - yl)aMino]Methylidene] - 2,2 - diMethyl - 1,3 - dioxane - 4,6 - dione(25063-69-8)

Safety Data

• Hazardous Substances Data: 25063-69-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
5 [[(6 Methoxypyridin 3 yl)aMino]Methylidene] 2,2 diMethyl 1,3 dioxane 4,6 dione is used as a building block for the synthesis of new compounds with potential therapeutic applications. Its unique structure and functional groups make it a valuable component in the development of innovative pharmaceuticals.
Used in Analytical Chemistry:
In the field of analytical chemistry, 5 [[(6 Methoxypyridin 3 yl)aMino]Methylidene] 2,2 diMethyl 1,3 dioxane 4,6 dione serves as a reference standard. Its well-defined structure and properties allow for accurate measurements and comparisons in various analytical techniques, ensuring reliable results in chemical analyses.
While the provided materials do not specify any industry-specific applications, the potential uses of 5 [[(6 Methoxypyridin 3 yl)aMino]Methylidene] 2,2 diMethyl 1,3 dioxane 4,6 dione in pharmaceutical research and analytical chemistry demonstrate its versatility and importance in the scientific community. Further research and development may reveal additional applications and industries where this compound can be utilized effectively.

Upstream product

• 6628-77-9 6-methoxy-pyridin-3-ylamine 
• 2033-24-1 cycl-isopropylidene malonate 
• 122-51-0 orthoformic acid triethyl ester 
• 15568-85-1 5-methoxymethylene-2,2-dimethyl-1,3-dioxane-4,6-dione 
• 149-73-5 trimethyl orthoformate 

Downstream Products

• 23443-25-6 6-methoxy-1,5-naphthyridin-4-ol 
• 23443-25-6 6-methoxy-1,5-naphthyridin-4(1H)-one 
• 1431984-59-6 C₂₅H₃₀N₆O₂ 
• 1431984-60-9 C₃₀H₄₁N₇O₂ 
• 1431984-75-6 C₂₃H₂₄F₂N₆ 
• 1431984-74-5 C₂₃H₂₄F₂N₆ 
• 1431984-61-0 C₂₆H₂₈N₈O₄S 
• 1431984-62-1 C₂₃H₂₁N₅O₂ 
• 1431984-65-4 2,8-dichloro-7-(1-methyl-1H-pyrazol-4-yl)-1,5-naphthyridine 
• 1431984-85-8 C₂₅H₂₈N₆O₂ 
• 1431984-63-2 C₂₂H₂₂BrN₅O₂ 
• 1431984-64-3 C₂₄H₂₃N₇O₂ 
• 1431985-36-2 C₂₀H₁₉N₅O₂ 
• 1431985-37-3 C₂₈H₃₇N₅O₃Si 

Relevant articles and documents

SIX-MEMBERED AND SIX-MEMBERED HETEROCYCLIC COMPOUND AND USES THEREOF SERVING AS PROTEIN RECEPTOR KINASE INHIBITOR

Provided are a preparation and applications of a six-membered fused with six-membered heterocyclic compound, specifically, provided in the present invention is a compound as represented by formula I as follows, where the definitions of the groups are as described in the description. The compound has TRK kinase inhibiting activity and can serve as a pharmaceutical composition for treating TRK dysfunction-related diseases.

Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria

A novel 2,8-disubstituted-1,5-naphthyridine hit compound stemming from the open access Medicines for Malaria Venture Pathogen Box formed a basis for a hit-to-lead medicinal chemistry program. Structure-activity relationship investigations resulted in compounds with potent antiplasmodial activity against both chloroquine sensitive (NF54) and multidrug resistant (K1) strains of the human malaria parasite Plasmodium falciparum. In the humanized P. falciparum mouse efficacy model, one of the frontrunner compounds showed in vivo efficacy at an oral dose of 4 × 50 mg·kg-1. In vitro mode-of-action studies revealed Plasmodium falciparum phosphatidylinositol-4-kinase as the target.

Process for Manufacturing a Naphthyridine Derivative

The invention relates to a process and synthetic intermediates that can be used for manufacturing the compound of formula (1-6) which is a synthetic intermediate useful in the preparation of antibiotic compounds.

Aurora Kinase Modulators and Method of Use

The present invention relates to chemical compounds having a general formula I wherein A1-8, D′, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

A one-pot diazotation-fluorodediazoniation reaction and fluorine gas for the production of fluoronaphthyridines

Several synthetic routes to 7-fluoro-2-methoxy-8-methyl-1,5-naphthyridine (1) are presented, and their suitability for scale-up is discussed. The way of introducing the fluorine atom is crucial. Early routes start from commercially available fluorinated building blocks or employ F+ reagents like SelectFluor and delivered up to 70 kg of 7-fluoro-2-methoxy-1,5-naphthyridine (18). To prepare for larger scales, the focus turned to the use of HF or elemental fluorine, both one of the cheapest sources of fluorine. The first method, a one-pot diazotation-fluorodediazoniation with 6-methoxy-1,5- naphthyridin-3-amine (9) in HF gave the fluorinated naphthyridine 18 in high yield and purity without isolation of the unstable diazonium salt, the latter being a severe drawback of the related Balz-Schiemann protocol. The second method relies on the use of fluorine gas for a surprisingly selective ortho-fluorination of 6-methoxy-1,5-naphthyridin-4-ol (10).

BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS

Novel bridged bicyclic compounds are disclosed herein, along with their pharmaceutically acceptable salts, hydrates and prodrugs. Also disclosed are compositions comprising such compounds, methods of preparing such compounds and methods of using such compounds as antibacterial agents. The disclosed compounds, their pharmaceutically acceptable salts, hydrates and prodrugs, as well as compositions comprising such compounds, salts, hydrates and prodrugs, are useful for treating bacterial infections and associated diseases and conditions.

PROCESS FOR MANUFACTURING A NAPHTHYRIDINE DERIVATIVE

The invention relates to a process and synthetic intermediates that can be used for manufacturing the compound of formula (1-6) which is a synthetic intermediate useful in the preparation of antibiotic compounds.

NEW COMPOUNDS

The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

AURORA KINASE MODULATORS AND METHOD OF USE

The present invention relates to chemical compounds having a general formula I {INSERT STRUCTURE HERE} wherein A1-8, D,, L1, L2, R1, R6-8 and n are defined herein, and synthetic intermediates, which are capable of modulating various protein kinase receptor enzymes and, thereby, influencing various disease states and conditions related to the activities of such kinases. For example, the compounds are capable of modulating Aurora kinase thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of Aurora kinase.

Strategic studies in the syntheses of novel 6,7-substituted quinolones and 7- or 6-substituted 1,6- and 1,7-naphthyridones

This paper describes the different strategies devised and applied to overcome the selectivity issues in the syntheses of 6,7-disubstituted-1H-quinolin-4-one, 7-substituted-1H-1,6-naphthyridin-4-one and 6-substituted-1H-1,7-naphthyridin-4-one derivatives. They allowed us to improve the overall yields and the scaling-up feasibility. Several examples illustrate these strategies with their advantages and drawbacks.